Lundbeck eyes major breakthrough for brain diseases
At pharmaceutical firm Lundbeck, EVP Keld Flintholm Jørgensen thinks quantam leaps are happening when it comes to brain diseases.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
Following a tumultuous time period involving a near-empty pipeline, multiple drug failures and a plummeting share price, the management of Lundbeck sees light at the end of the tunnel in its core area for central nervous system (CNS) diseases, which may have the potential to create a new era for the Danish pharmaceutical company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck carries on Rexulti study after new analysis
For subscribers
.jpg&w=384&q=75)
